Apitoria Pharma Private Limited – FDA 483, Jul 1, 2016

This FDA Form 483 document outlines observations made during an inspection of a manufacturing facility. The inspection identified three key deficiencies related to the firm's quality system and manufacturing operations.

Firstly, the firm failed to establish adequate procedures for the cleaning and maintenance of equipment. This indicates a potential risk of contamination or equipment malfunction due to insufficient upkeep protocols.

Secondly, the manufacturing process for Product X was not adequately validated. This suggests that the firm has not demonstrated that its process consistently produces a product meeting its predetermined specifications and quality attributes, raising concerns about product quality and consistency.

Finally, the firm did not maintain proper records of batch production and control. This deficiency impacts traceability, quality control, and the ability to investigate deviations or product issues, as essential documentation is either missing or incomplete.

These observations collectively point to significant issues within the firm's quality system, specifically concerning equipment management, process validation, and record-keeping. Addressing these deficiencies is crucial for the firm to ensure compliance with regulatory requirements and maintain product quality and safety.